The pharmaceutical industry’s billion-dollar practice of inflating drug prices and shielding itself from accountability has brought immense public outcry and inspired a profusion of legal reforms. This Article explains why federal law should not be interpreted as preempting state regulation of pharmaceutical supply chains. Insulin prices in the United States have spiked shockingly high compared to those in other developed countries. This Article’s second contribution is its timely, novel analysis of the ongoing court challenges to state law reforms aiming to address healthcare industry anticompetitive practices. It further describes the collusive practices among these actors that artificially inflate drug prices, including formulary exclusion, rebates, spread pricing, convoluted fees, and preferred pharmacy status.

Source: CNN December 22, 2025 02:11 UTC